FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Methods for monopolar renal neuromodulation

Medtronic Ardian Luxembourg S.a.r.l.

Methods for monopolar renal neuromodulation

Methods for therapeutic renal neuromodulation

Medtronic Ardian Luxembourg S.a.r.l.

Methods for therapeutic renal neuromodulation

Methods for therapeutic renal neuromodulation

Methods for renal neuromodulation

Date/App# patent app List of recent Cytokine-related patents
03/19/15
20150080885
 Methods for bilateral renal neuromodulation patent thumbnailMethods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080884
 Methods for monopolar renal neuromodulation patent thumbnailMethods for monopolar renal neuromodulation
Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080873
 Methods for therapeutic renal neuromodulation patent thumbnailMethods for therapeutic renal neuromodulation
Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080481
 Methods for renal neuromodulation patent thumbnailMethods for renal neuromodulation
Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
03/19/15
20150080419
 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same patent thumbnail5-substituted quinazolinone derivatives and compositions comprising and methods of using the same
Provided are 5-substituted quinazolinone compounds, for example, of formula (i), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use for treating angiogenesis or cytokine related disorders, and pharmaceutical compositions of these compounds are disclosed..
Celgene Corporation
03/19/15
20150079190
 Immortalized cell compositions and compositions derived therefrom patent thumbnailImmortalized cell compositions and compositions derived therefrom
The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom.
Stemnion, Inc.
03/19/15
20150079116
 Diagnostic tools for response to 6-thiopurine therapy patent thumbnailDiagnostic tools for response to 6-thiopurine therapy
Nk cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein..
The Regents Of The University Of California
03/19/15
20150079048
 Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling patent thumbnailMethod for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150079026
 Controlled release formulations for the induction and proliferation of blood cells patent thumbnailControlled release formulations for the induction and proliferation of blood cells
The absence of regulatory t cells (treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of treg through in situ treg expansion or induction is contemplated herein as a treatment option for these disorders.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
03/12/15
20150072889
 Systems and methods for detecting infectious diseases patent thumbnailSystems and methods for detecting infectious diseases
Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.
03/12/15
20150072338

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.
03/12/15
20150071967

Tolerisation-inducing composition


The present invention relates to a composition comprising a tolerogenic peptide and a gsk-3 inhibitor and uses thereof. The invention also relates to the use of a gsk-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines.
University Of Bristol
03/12/15
20150071960

Human inkt cell activation using glycolipids with altered glycosyl groups


Glycosphingolipids (gsls) bearing α-glucose (α-glc) that preferentially stimulate human invariant nkt (inkt) cells are provided. Gsls with α-glucose (α-glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-gal) are disclosed.
Academia Sinica
03/05/15
20150064787

Host cell modification with artificial endosymbionts


The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell.
Bell Biosystems, Inc.
03/05/15
20150064215

Therapeutic delivery and expression system, methods and uses thereof


Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (ikde) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium.
The University Of Hong Kong
03/05/15
20150064199

Cancer therapy using beta glucan and antibodies


The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble beta (1,3; 1,6) glucan (nsg) enhances the tumoricidal activity of the innate immune system by binding to the c3 complement protein receptor cr3.
University Of Louisville Research Foundation, Inc.
03/05/15
20150064179

Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)


Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1l-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof..
Biotest Ag
02/26/15
20150057175

Method for monitoring hiv specific t cell responses


The invention relates to a method and a diagnostic kit for monitoring hiv specific t cell responses and identifying subjects capable of controlling hiv progression or preventing hiv infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays.
InstituciÓ Catalana De Recerca I Estudis AvanÇats
02/26/15
20150056680

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses


The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc.
02/26/15
20150056222

Anti-prlr antibodies and uses thereof


The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056221

Anti-prlr antibodies and uses thereof


The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056215

Methods of treating proliferative disorders with malate or derivatives thereof


The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine..
Beth Israel Deaconess Medical Center, Inc.
02/26/15
20150056160

Chemically induced intracellular hyperthermia


An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation..
St. Jude Pharmaceuticals, Inc.
02/19/15
20150051441

Embryo implantation


The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue..
Ostara Biomedical Ltd
02/19/15
20150051156

Method of treating leukemia using rice prolamin


The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (pbmc) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells.
Mackay Memorial Hospital
02/19/15
20150050715

Stably tethered structures of defined compositions with multiple functions or binding specificities


The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor.
Ibc Pharmaceuticals, Inc.
02/19/15
20150050251

Cosmetic preparations


The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as amp cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or accs), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination..
Stemnion, Inc.
02/12/15
20150045422

Influenza treatment using targeted transient ribosomal inhibition


Novel methods are presented for treating influenza by using targeted transient ribosomal inhibition (ttri), with ttri drugs administered by inhalation, to silence expression of every protein underlying the etiology and pathology of the influenza infection, and without adversely effecting normal cells in the lungs. The therapeutic effect is dual antiviral and anti-inflammatory activity which is localized to the lungs.
02/12/15
20150044717

Devices and methods for observing eukaryotic cells without cell wall


The present invention relates to methods and devices for observing eukaryotic cells devoid of cell wall, in particular for observing the cytokinetic ring, the device comprising a plurality of wells suitable for containing only one single eukaryotic cell and characterized in that the dimensions of the wells constrain the cells into an oblong shape with a long axis parallel to the depth of the wells.. .
Inserm (institut National De La Sante Et De La Recherche Medicale)
02/12/15
20150044316

Method for preparing a purified extract of lonicera japonica thunberg and the composition comprising the same for preventing and treating sepsis and septic shock


The present invention relates to a method for preparing a purified extract of lonicera japonica thunberg and the composition comprising the same for preventing and treating sepsis and septic shock. The purified extract of purified extract of lonicera japonica thunberg potent antisepsis activity in severe sepsis clp model test, the effect on mods, and the inhibitory effect on various pro-inflammatory cytokines such as tnf-alpha, il-1beta, ifn-gamma, hmgb-1 etc, as well as it showed unexpectedly synergistic effect on the treatment of sepsis and septic shock in case of combining with the commercially available anti-septic agent such as broad-spectrum anti-biotic to the person skilled in the art, therefore, it can be useful in treating and preventing the sepsis and septic shock as a medicament and health functional food..
Huons Co., Ltd.
02/12/15
20150044258

Process for t cell expansion


An in vitro expansion process for rapid expansion of antigen specific t cells, such as allogeneic antigen specific t cells comprising the steps culturing in a gas permeable vessel a population of pbmcs (such as allogeneic pbmcs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of t cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to t cell populations generated by and obtained from the method and the use of same in therapy..
Cell Medica Limited
02/12/15
20150044166

Compositions and methods for treatment of exercise-induced pulmonary hemorrhage or nasopharyngeal cicatrix


Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (eiph) and nasopharyngeal cicatrix (nc) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors.
Riddle Institute
02/12/15
20150044134

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami
02/05/15
20150038542

Uses of selective inhibitors of hdac8 and treatment of inflammatory conditions


Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of pro-inflammatory cytokines by administering an hdac8-selective inhibitor compound.
Pharmacyclics, Inc.
02/05/15
20150037887

Method for producing nk cell-enriched blood preparation


It is intended to provide a method for producing an nk cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing nk cells, etc. In blood collected from an organism.
Biotherapy Institute Of Japan
02/05/15
20150037283

Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases


Disclosed are compositions and methods comprising combinations of anti-cd74 antibodies with a therapeutic agent that is attached to the anti-cd74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from cd74, such as cd19, cd20, cd21, cd22, cd23, cd37, cd40, cd40l, cd52, cd80, il-6, cxcr4 or hla-dr.
Ibc Pharmaceuticals, Inc.
01/29/15
20150031649

Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis


A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
Voltarra Pharmaceuticals, Inc.
01/29/15
20150031625

Targeted vectors for cancer immunotherapy


This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject.
The University Of Southern California
01/29/15
20150030633

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh
01/29/15
20150030562

Methods of treating or preventing viral diseases by blocking interleukin-21


The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (il)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of immune cells in a mammal comprising administering to the mammal an il-21 blocking agent in an amount effective to reduce the activation or recruitment of immune cells in the mammal.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
01/22/15
20150025603

Methods and multi-vessel renal neuromodulation


Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
01/22/15
20150025223

System and producing interleukin receptor antagonist (ira)


The present invention relates to a system and method for producing high levels of autologous il-1ra cytokine, comprising: a blood collection vessel (1), a cover (4), a portion of separation gel (2), an anticoagulant portion (3), a plasma collection syringe comprising a sharp needle (9), a buffy coat collection syringe (11) and an incubation tube with cover (15). The vessel is adapted such that, when containing the whole blood (5), and centrifuged after treatment, yields separation fractions comprising, a first fraction of rbcs sediment (6), a second fraction of said gel (2), a third fraction comprising wbcs, platelets and), and fourth fraction of plasma solution (8)..
Estar Technologies Ltd
01/22/15
20150025009

Collagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration


Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.3871

3233

3 - 0 - 73